samedan logo
 
 
spacer
home > ict > autumn 2017 > end point: a costly cause
PUBLICATIONS
International Clinical Trials

End Point: A Costly Cause

Our sister publication, Pharmafile (in its spring 2017 edition), listed the predicted top 50 selling products in the world in 2022. I was astonished to note that the vast majority of these products are biotechnology-based products rather than traditional molecules. Fewer than 10 small molecules feature on this list. In a separate article, Pharmafile discusses the world of $100,000 products and how this will impact on the future of healthcare. If you examine the list of these drugs a little further, you will note that the majority of them are not for rare conditions, but unusual ones. I remember that while working for the agrochemical industry, a development scientist at one of the leading US companies told me that, if the new pesticide did not work on corn or cotton, it would never make economic sense to develop it. In the same group, a farmer who grew courgettes said ‘What hope have I got for the future then?’ The pharmaceutical industry is not yet in this parlous condition, but it may be that the era of the blockbuster is ending and precision medicine will take its place.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer

spacer
Dr Graham Hughes
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Sharp announces preferred partner agreement with Berkshire Sterile Manufacturing

Sharp, a global leader in contract packaging and clinical supply services, part of UDG Healthcare plc, has confirmed a preferred partner agreement with innovative sterile manufacturer Berkshire Sterile Manufacturing (BSM).
More info >>

White Papers

Convergence in the Pharmaceutical Market

PCI Pharma Services

Convergence is currently playing a large part in the growth of the pharmaceutical market. The need for convergence is due to many factors including the declining economy and high competition within the sector. There are many convergences within this sector to date; these include the convergence of food based products with medical and health products and the convergence of prescription drugs to over the counter (OTC) products. Although convergence is helping the pharmaceutical industry expand and develop, it also poses some challenges; these include the regulatory outlook and counterfeiting.
More info >>

 
Industry Events

INTERPHEX 2019

2-4 April 2019, Javits Center, New York

At INTERPHEX, find all of the State-of-the-Art Solutions you need to Cost Effectively Develop and Manufacture Product. INTERPHEX is a premier pharmaceutical, biotechnology, and medical device development and manufacturing event and sponsored by Parenteral Drug Association (PDA). Dedicated to Innovation, Technologies and Knowledge, the show focuses on the entire product development life cycle.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement